BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition

While several systemic therapies are approved for cutaneous T cell lymphoma (CTCL), a non-Hodgkin lymphoma of skin-homing T cells that may involve lymph nodes and peripheral blood in advanced stages, relapses are common. Mutational analysis of CTCL cells has revealed frequent amplification of the MY...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sa Rang, Lewis, Julia M., Cyrenne, Benoit M., Monico, Patrick F., Mirza, Fatima N., Carlson, Kacie R., Foss, Francine M., Girardi, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044378/
https://www.ncbi.nlm.nih.gov/pubmed/30018745
http://dx.doi.org/10.18632/oncotarget.25670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044378/
https://www.ncbi.nlm.nih.gov/pubmed/30018745
http://dx.doi.org/10.18632/oncotarget.25670

Ejemplares similares